EGFR and head and neck squamous cell carcinoma: Cetuximab is the only approved EGFR monoclonal antibody (mAb), either in combination with radiotherapy for HNSCC patients not suitable for concurrent platinum chemotherapy, or in combination with platinum-based chemotherapy in recurrent or metastatic HNSCC, in the UK.